Suggestions
Morgan Cheatham
Vice President at Bessemer Venture Partners | bio, healthcare, AI | MD Candidate
Professional Background
Morgan Cheatham is a distinguished venture capitalist and medical trainee known for his keen focus on healthcare and life sciences investments. Currently, Morgan is investing at Bessemer Venture Partners, where he specializes in leading investment initiatives from seed to growth stages. Born with a vision to improve patient care by integrating computational techniques, Morgan's work emphasizes the critical applications of computation to aid healthcare professionals in delivering effective treatments. His extensive experience and commitment have positioned him as a notable figure in not only venture capital but also in the medical research field.
In conjunction with his role at Bessemer, Morgan is pursuing a Doctor of Medicine (MD) degree from The Warren Alpert Medical School of Brown University, underpinning his investment strategies with a deep understanding of clinical needs and nuances. Morgan’s research interests lie predominantly in bioinformatics, a field where he is making significant contributions through various collaborations. He is currently associated with the Stanford Institute for Human-Centered AI, where he investigates the clinical applications and validation of large language models (LLMs). Moreover, his work at the Zitnik Lab at the Harvard Department of Biomedical Informatics involves the development of large pre-trained AI models that aim to address complex questions in the biomedical domain.
Education and Achievements
Morgan's journey into the world of science and technology started at Thomas Jefferson High School for Science and Technology, where he laid the foundation for his future endeavors in computational decision sciences. He then achieved his Bachelor of Science (B.Sc.) in Computational Decision Sciences from Brown University, which served as a springboard for his advanced studies in medicine. Morgan's current pursuit of an MD blends seamlessly with his extensive background in data science and analytics, allowing him to bridge the gap between technology development and healthcare delivery.
Adding to his qualifications, Morgan holds esteemed positions within various organizations, showcasing his leadership and commitment to advancing healthcare through innovation. He has formerly held the role of Interim Chief Executive Officer at FOLX Health, where he helped facilitate innovative healthcare solutions for the LGBTQ+ community. His dedication to diversity in healthcare is further exemplified by his involvement as a Board Director at FOLX Health.
Morgan's reputation in the industry was further recognized when he was featured on Forbes' 30 Under 30 list, adding a significant accolade to his already impressive portfolio of achievements. His forward-thinking approach and expertise in both venture capital and medicine have made him a key figure in the intersection of health technology and investment.
Notable Contributions and Engagements
Morgan is a prolific writer and engages with the research community through various platforms. He is a member of the New England Journal of Medicine (NEJM) AI Editorial Team, encouraging others to submit their critical research in the field of AI. Additionally, he shares insights on his personal Substack and contributes to “Decoding Bio,” where he explores and decodes advancements in the biotechnology sector. His insightful writings reflect his commitment to bridging the gap between complex scientific research and accessible understanding, fostering an informed public discourse around healthcare technology.
Throughout his career, Morgan has also been involved in other significant roles, including a Limited Partner at Silver Beech Capital Management and First Close Partners, as well as his tenure as an Investment Banking Analyst at Goldman Sachs and Data Scientist at Kyruus. These experiences have not only enriched his investment perspective but have armed him with critical financial acumen that places him at the forefront of healthcare venture capital.
Conclusion
In summary, Morgan Cheatham embodies the spirit of innovation, linking the worlds of healthcare and technology through his work in venture capital and medical research. His dual pursuit of a medical degree while making strategic investments in healthcare technology is a testament to his dedication to improving patient care and advancing the medical field. With a rich background in computational sciences, invaluable collaborations, and a commitment to diversity and inclusion in healthcare, Morgan is poised to make lasting contributions to both the scientific and business communities. His efforts inspire many, presenting an encouraging outlook on the future of healthcare technology and investment.
title
Professional Background
Education and Achievements
Notable Contributions and Engagements
Conclusion
Highlights
after a week of conversations at JPM, the patterns are clear, and they align with our thesis. capital, talent, and economics are rapidly reorganizing around three key axes: computation, precision, and prevention.
next week, we're releasing the Breyer Capital 2026 Healthcare & Life Sciences Predictions—ten inflection points where technological maturity meets market readiness, featuring perspectives from our top portfolio companies.
going into the long weekend, here are three predictions we feel most strongly about:
today we are excited to announce the appointment of Dr. Bret Bostwick as Venture Advisor at Breyer Capital.
@bretbostwick is a medical geneticist who has invented and scaled therapies from discovery into the clinic, including co-inventing the first gene-silencing therapy shown to work in the human brain. he brings a rare combination of scientific vision, translational rigor, and clinical judgment.


